Key result
DOACs linked to lower risk of incident GI bleeding compared to antiplatelets.
Why the study?
Antithrombotic drug-drug interactions impact patient safety, prompting evaluation of the association between interacting drugs, direct oral anticoagulants, antiplatelets, warfarin, and incident gastrointestinal bleeding risk.
Does DOAC exposure reduce incident gastrointestinal bleeding compared to antiplatelets in adults?
Observational
Does DOAC exposure reduce incident gastrointestinal bleeding compared to antiplatelets in adults?
p-value: p=0.006
In a claims-based analysis, DOACs were associated with a lower risk of incident gastrointestinal bleeding compared to antiplatelets, with bleeding risk primarily driven by advanced age and comorbidities.
Hypothesis-generating for lower GI bleeding risk with DOACs versus antiplatelets; should not yet change prescribing pending randomized confirmation.
BACKGROUND: Antithrombotic drug-drug interactions (DDIs) impact patient safety. This study used causal inference framework to examine the association between interacting drugs, direct oral anticoagulants (DOACs), antiplatelets, warfarin and incident gastrointestinal (GI) bleeding risk. RESEARCH DESIGN AND METHODS: Data from Merative MarketScan commercial and Medicare claims (2013-2021), enriched with Micromedex data were used. Adults (≥18 years) with antithrombotics claims were included. Incident GI bleeding was primary outcome. Adaptive post-double selection using least absolute shrinkage and selection operator (LASSO) was implemented for variable selection. Following propensity score matching, final estimates were obtained from weighted logistic models. RESULTS: = 0.006). None of the interacting drugs reached statistical significance, bleeding risk was driven by age (>70 years) and comorbidities. CONCLUSIONS: Within a causal inference framework, DOACs exposure was associated with less risk of GI bleeding compared to antiplatelets. However, class-level grouping may mask individual drug-specific metabolic risks. IRB: The protocol (STUDY00016941) was reviewed and received exemption determination by the University of Minnesota Institutional Review Board.
No takes yet. Share an insight, caveat, or question.
Pradhan et al. (2026) conducted an observational in Antithrombotics use. DOACs vs. Antiplatelets was evaluated on Incident GI bleeding (p=0.006). DOAC exposure was associated with a lower risk of incident gastrointestinal bleeding compared to antiplatelets (P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: